BETHESDA, Md., Nov. 5, 2025 /PRNewswire/ -- Precision Biologics, Inc. announces in vitro and in vivo efficacy of its novel...
BETHESDA, Md., Sept. 19, 2025 /PRNewswire/ -- Precision Biologics, Inc. reports that in vitro and in vivo...
Precision Biologics, Inc. will present new data on a newly developed Antibody-Drug Conjugate PB-223 ADC...
Precision Biologics, Inc. CEO Philip M Arlen, MD will give the Keynote speech, and also...
An article titled “Cancer Vaccines-Improving Their Aim” in the current April 2025 issue of trade...
Precision Biologics announces that our Chief Scientific Officer, Kwong "Al" Tsang, will deliver a talk...
Precision Biologics announces that our Director of Research & Development, Massimo Fantini, PhD, will deliver...
Precision Biologics, Inc. CEO, Philip M Arlen, MD, will participate on an interactive panel (Day...
Precision Biologics will present affinity maturation and characterization of a novel core 2 O-glycan epitope...
Precision Biologics, Inc. will present novel data about affinity maturation and characterization of a novel...